High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness

Cancer Medicine

Volumn 5, Issue 6, 2016, Pages 1022-1030

  Long, Elodie ^a,b   Ilie, Marius ^a,b   Bence, Coraline ^b   Butori, Catherine ^b   Selva, Eric ^b   Lalvée, Salomé ^b   Bonnetaud, Christelle ^b   Poissonnet, Gilles ^c   Lacour, Jean Philippe ^d   Bahadoran, Philippe ^d,e   Brest, Patrick ^a   Gilson, Eric ^a,d   Ballotti, Robert ^e   Hofman, Véronique ^a,b   Hofman, Paul ^a,b,f,g  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b PASTEUR HOSPITAL   (France)

^c Cancer Center   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^f Cancer Research Association (ARC) Labelled Team   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Circulating tumor cells; circulating tumor microemboli; immunocytochemistry; Metastatic melanoma; prognosis

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PROTEIN S 100; TELOMERIC REPEAT BINDING FACTOR 2; TRANSCRIPTION FACTOR SOX10;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CIRCULATING TUMOR MICROEMBOLUS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; ISOLATED CIRCULATING TUMOR CELL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NEVUS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR EMBOLISM;

EID: 84991521375     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.661     Document Type: Article

References (31)

1. Alix-Panabieres, C., and K. Pantel. 2013. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 59:110–118.
2. Greene, B. T., A. D. Hughes, and M. R. King. 2012. Circulating tumor cells: the substrate of personalized medicine? Front. Oncol. 2:69.
3. Koyanagi, K., S. J. O'Day, R. Gonzalez, et al. 2005. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J. Clin. Oncol. 23:8057–8064.
4. Maheswaran, S., and D. A. Haber. 2010. Circulating tumor cells: a window into cancer biology and metastasis. Curr. Opin. Genet. Dev. 20:96–99.
5. Yu, M., S. Stott, M. Toner, S. Maheswaran, and D. A. Haber. 2011. Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol. 192:373–382.
6. Clawson, G. A., E. Kimchi, S. D. Patrick, et al. 2012. Circulating tumor cells in melanoma patients. PLoS ONE 7:e41052.
7. Karakousis, G., R. Yang, and X. Xu. 2013. Circulating melanoma cells as a predictive biomarker. J. Invest. Dermatol. 133:1460–1462.
8. Krebs, M. G., R. L. Metcalf, L. Carter, G. Brady, F. H. Blackhall, and C. Dive. 2014. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. Clin. Oncol. 11:129–144.
9. Palmieri, G., M. Strazzullo, P. A. Ascierto, S. M. Satriano, A. Daponte, and G. Castello. 1999. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J. Clin. Oncol. 17:304–311.
10. Pinzani, P., C. Mazzini, F. Salvianti, et al. 2010. Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression. Melanoma Res. 20:303–310.
11. Khoja, L., P. Lorigan, C. Dive, U. Keilholz, and A. Fusi. 2015. Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann. Oncol. 26:33–39.
12. De Giorgi, V., P. Pinzani, F. Salvianti, et al. 2010. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J. Invest. Dermatol. 130:2440–2447.
13. Hofman, V., M. Ilie, E. Long-Mira, et al. 2013. Usefulness of Immunocytochemistry for the Detection of the BRAF(V600E) Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients. J. Invest. Dermatol. 133:1378–1381.
14. Khoja, L., P. Shenjere, C. Hodgson, et al. 2014. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res. 24:40–46.
15. Ma, Y. C., L. Wang, and F. L. Yu. 2013. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology. Technol. Cancer Res. Treat 12:295–309.
16. Khoja, L., P. Lorigan, C. Zhou, et al. 2013. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. 133:1582–1590.
17. Gray, E. S., A. L. Reid, S. Bowyer, et al. 2015. Circulating Melanoma Cell Subpopulations: their Heterogeneity and Differential Responses to Treatment. J. Invest. Dermatol. 135:2040–2048.
18. Ordonez, N. G. 2014. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum. Pathol. 45:191–205.
19. Graf, S. A., C. Busch, A. K. Bosserhoff, R. Besch, and C. Berking. 2014. SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity. J. Invest. Dermatol. 134:2212–2220.
20. Loftus, S. K. 2013. Decreased melanoma proliferation and cell survival: turn down your SOX10. Pigment Cell Melanoma Res. 26:3–4.
21. Oba, J., T. Nakahara, S. Hayashida, et al. 2011. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. J. Am. Acad. Dermatol. 65:1152–1160.
22. Thomas-Pfaab, M., J. P. Annereau, C. Munsch, et al. 2013. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. J. Dermatol. Sci. 69:105–113.
23. Biroccio, A., A. Rizzo, R. Elli, et al. 2006. TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. Eur. J. Cancer 42:1881–1888.
24. Hofman, V., C. Bonnetaud, M. I. Ilie, et al. 2011. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin. Cancer Res. 17:827–835.
25. Ilie, M., E. Long, C. Butori, et al. 2012. ALK-gene rearrangement, a comparative analysis on circulating tumour cells and tumour tissue from lung adenocarcinoma patients. Ann. Oncol. 23:2907–2913.
26. Graf, S. A., C. Busch, A. K. Bosserhoff, R. Besch, and C. Berking. 2014. SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity. J. Invest. Dermatol. 134:2212–2220.
27. Pitman, R. T., L. Wojdyla, and N. Puri. 2013. Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget 4:761–771.
28. Biroccio, A., J. Cherfils-Vicini, A. Augereau, et al. 2013. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat. Cell Biol. 15:818–828.
29. Scher, H. I., G. Heller, A. Molina, et al. 2015. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 33:1348–1355.
30. Cools-Lartigue, J., J. Spicer, B. McDonald, et al. 2013. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. 0000:000.
31. Uppal, A., S. C. Wightman, S. Ganai, R. R. Weichselbaum, and G. An. 2014. Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model. Theor. Biol. Med. Model 11:17.